{"id":40221,"date":"2025-08-27T13:37:51","date_gmt":"2025-08-27T05:37:51","guid":{"rendered":"https:\/\/flcube.com\/?p=40221"},"modified":"2025-08-27T13:37:52","modified_gmt":"2025-08-27T05:37:52","slug":"junshi-biosciences-reports-49-revenue-growth-in-h1-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40221","title":{"rendered":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025"},"content":{"rendered":"\n<p>Shanghai <strong>Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) released its interim financials for the first half of 2025, highlighting a <strong>49\u202f% year\u2011on\u2011year increase in total revenue<\/strong> and a <strong>36\u202f% reduction in loss attributable to owners<\/strong>.<\/p>\n\n\n\n<p><strong>Key Highlights<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>H1\u202f2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Total revenue<\/td><td>RMB\u202f1,168\u202fm<\/td><td>+49\u202f%<\/td><\/tr><tr><td>Loss attributable to owners<\/td><td>RMB\u202f413\u202fm<\/td><td>\u201336\u202f%<\/td><\/tr><tr><td>R&amp;D expenses<\/td><td>RMB\u202f745\u202fm<\/td><td>+36\u202f%<\/td><\/tr><tr><td>Cash &amp; financial assets (30\u202fJun\u202f2025)<\/td><td>RMB\u202f3,490\u202fm<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The strong revenue growth was largely driven by <strong>toripalimab (TUOYI\/LOQTORZI)<\/strong>, a PD\u20111 antibody that achieved <strong>RMB\u202f954\u202fm in domestic sales<\/strong>\u2014a 42\u202f% jump from the same period in 2024.<\/p>\n\n\n\n<p><strong>Toripalimab: Core Driver of Growth<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>12 approved indications in mainland China<\/strong>; <strong>10<\/strong> included in the 2025 NRDL.<\/li>\n\n\n\n<li>Expanded marketing approvals in multiple countries have sustained international sales momentum.<\/li>\n\n\n\n<li>Domestic sales accounted for <strong>82\u202f%<\/strong> of total revenue in H1\u202f2025.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cOur flagship product continues to deliver solid, repeatable demand across China\u2019s oncology market,\u201d said <strong>Mr. Wang Yong<\/strong>, CEO of Junshi Biosciences.<\/p>\n<\/blockquote>\n\n\n\n<p><strong>Pipeline &amp; R&amp;D Investment<\/strong><\/p>\n\n\n\n<p>Junshi\u2019s R&amp;D spend of RMB\u202f745\u202fm supports a diversified portfolio of next\u2011generation immunotherapies and targeted agents, including:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Candidate<\/th><th>Target<\/th><\/tr><\/thead><tbody><tr><td><strong>Bispecifics<\/strong><\/td><td>JS207 (PD\u20111\/VEGF)<\/td><td>Oncology<\/td><\/tr><tr><td><\/td><td>JS212 (EGFR\/HER3 ADC)<\/td><td>Solid tumours<\/td><\/tr><tr><td><strong>Monoclonals<\/strong><\/td><td>JS004 (tifcemalimab)<\/td><td>BTLA\u2011mediated cancers<\/td><\/tr><tr><td><\/td><td>JS015 (anti\u2011DKK1)<\/td><td>Bone\u2011metastatic disease<\/td><\/tr><tr><td><strong>Fusion Proteins<\/strong><\/td><td>JS213 (PD\u20111\/IL\u20112)<\/td><td>Tumour microenvironment<\/td><\/tr><tr><td><strong>ADC<\/strong><\/td><td>JS107 (Claudin\u201118.2)<\/td><td>GI cancers<\/td><\/tr><tr><td><strong>Small\u2011Molecule<\/strong><\/td><td>JS105 (PI3K\u2011\u03b1 inhibitor)<\/td><td>Targeted therapy<\/td><\/tr><tr><td><strong>Bispecific<\/strong><\/td><td>JS214 (VEGF\/TGF\u2011\u03b2)<\/td><td>Angiogenesis block<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>These assets aim to deepen Junshi\u2019s therapeutic reach and bolster the company\u2019s long\u2011term growth trajectory.<\/p>\n\n\n\n<p><strong>Cash Position &amp; Strategic Outlook<\/strong><\/p>\n\n\n\n<p>With <strong>RMB\u202f3.49\u202fb<\/strong> in liquid assets, Junshi maintains a solid cash runway to fund ongoing trials, commercialization, and potential acquisitions. The company remains focused on scaling toripalimab, accelerating pipeline candidates, and exploring international partnership opportunities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released its interim financials for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,27,899,900],"class_list":["post-40221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-finanical-reports","tag-hkg-1877","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences (1877.HK\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&amp;D spend climbs 36% to RMB\u202f745\u202fm.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40221\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences (1877.HK\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&amp;D spend climbs 36% to RMB\u202f745\u202fm.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40221\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T05:37:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-27T05:37:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025\",\"datePublished\":\"2025-08-27T05:37:51+00:00\",\"dateModified\":\"2025-08-27T05:37:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2704.webp\",\"keywords\":[\"Biotech\",\"Finanical Reports\",\"HKG: 1877\",\"SHA: 688180\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40221#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40221\",\"name\":\"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2704.webp\",\"datePublished\":\"2025-08-27T05:37:51+00:00\",\"dateModified\":\"2025-08-27T05:37:52+00:00\",\"description\":\"Shanghai Junshi Biosciences (1877.HK\\\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&D spend climbs 36% to RMB\u202f745\u202fm.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40221\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2704.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2704.webp\",\"width\":1080,\"height\":608,\"caption\":\"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40221#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences (1877.HK\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&D spend climbs 36% to RMB\u202f745\u202fm.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40221","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025","og_description":"Shanghai Junshi Biosciences (1877.HK\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&D spend climbs 36% to RMB\u202f745\u202fm.","og_url":"https:\/\/flcube.com\/?p=40221","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T05:37:51+00:00","article_modified_time":"2025-08-27T05:37:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40221#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40221"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025","datePublished":"2025-08-27T05:37:51+00:00","dateModified":"2025-08-27T05:37:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40221"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40221#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","keywords":["Biotech","Finanical Reports","HKG: 1877","SHA: 688180"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40221#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40221","url":"https:\/\/flcube.com\/?p=40221","name":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40221#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40221#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","datePublished":"2025-08-27T05:37:51+00:00","dateModified":"2025-08-27T05:37:52+00:00","description":"Shanghai Junshi Biosciences (1877.HK\/688180.SH) posted a 49% YoY rise in first\u2011half 2025 revenue to RMB\u202f1,168\u202fm, driven by toripalimab sales. The company\u2019s cash balance remains strong at RMB\u202f3,490\u202fm and R&D spend climbs 36% to RMB\u202f745\u202fm.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40221#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40221"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40221#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","width":1080,"height":608,"caption":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40221#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Reports 49% Revenue Growth in H1\u202f2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2704.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40221"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40221\/revisions"}],"predecessor-version":[{"id":40223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40221\/revisions\/40223"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40222"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}